Rectal Shedding of SARS-CoV-2 May Persist for Up to 7 Weeks
The goal of this study was to examine the time sequences of oral and fecal viral shedding in patients with coronavirus disease 2019 (COVID-19).
All articles by Emily Pond
Efficacy Profiles of Minimally Invasive Colorectal Screening Techniques
This study compared the effectiveness of both CT colonography and colon capsule endoscopy in detecting neoplastic lesions vs colonoscopy among patients in a colorectal cancer screening program with positive fecal immunochemical tests.
Premature Deaths From Alcoholic Liver Disease Trend Upward Over 2 Decades
Study data have identified an upward trend in premature deaths associated with alcoholic liver disease by sex and race.
Liver Resection May Close Racial Gap in Overall Survival Among Patients With Colorectal Liver Metastasis
Overall survival is significantly lower among Black patients with colorectal liver metastases compared with other races.
Outcomes of Creatine Kinase Levels in Tofacitinib-Treated Ulcerative Colitis Examined
Although tofacitinib may result in elevated creatine kinase levels, effects are reversible and not associated with significant adverse events.
COVID-19-Related Delays in CRC Screening Expected to Cause Increased Mortality
The potential consequences of delaying CRC screening due to the COVID-19 pandemic may lead to an increase in CRC mortality.
Systemic Inflammation in COVID-19 Could Be Responsible for Liver Damage
In patients with COVID-19, hepatic injury was associated with elevated levels of IL-6, CRP, ferritin, and lactate dehydrogenase.
Novel Biomarker Panel May Allow for Noninvasive Non-Alcoholic Steatohepatitis Diagnosis
The NIS4 biomarker panel may provide a means for clinicians to avoid unnecessary liver biopsies in patients at low risk for NASH.
Fecal Microbiota Transplantation Effectively Treats C difficile With IBD
Researchers conducted the first prospective study analyzing the efficacy of
fecal microbiota transplantation for patients with inflammatory bowel disease and C difficile infection.
Budesonide Orodispersible Tablets Effectively Bring EoE Into Remission
This phase 3 trial examined whether budesonide orodispersible tablets (0.5 mg or 1 mg, twice daily), with ≤48 weeks of treatment, was superior to placebo in maintaining remission of eosinophilic esophagitis.
-
Loading...
-
Loading...
Next post in Esophagus
